Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: A prospective study on 859 patients

Cancer Journal

Volumn 7, Issue 3, 2001, Pages 181-190

  Gion, Massimo ^a   Peloso, Lucia ^a   Mione, Riccardo ^a   Vignati, Giulio ^a   Fortunato, Antonio ^a   Saracchini, Silvana ^a   Biasioli, Roberto ^a   Gulisano, Marcella ^a   Cappelli, Gino ^a  

^a Ospedale Civile   (Italy)

Author keywords

Breast cancer; CA15.3; CEA; Decision criteria; Follow up; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035716995     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Breast cancer surveillance: A cost-effective strategy
2. Follow up of breast cancer in primary care vs specialist care: Results of an economic evaluation
3. Impact of follow-up testing on survival and health related quality of life in breast cancer patients: A multicenter randomized controlled trial
4. Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial
5. Evidence to support a change in follow-up policy for patients with breast cancer: Time to first relapse and hazard rate analysis
6. Annual hazard rates of recurrence for breast cancer after primary therapy
7. The rationale for early diagnosis of cancer: The example of breast cancer
8. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy
9. Molecular-target anticancer therapy: Challenges related to study design and choice of proper endpoints
10. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
11. 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer
12. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines
13. Value of CA15.3 in the follow-up of breast cancer patients
14. Comparison of CA15.3 and CEA in diagnosis and monitoring of breast cancer
15. Circulating CA15.3 levels in the postsurgical follow-up of breast cancer patients in non-malignant diseases
16. CA153, TPA and MCA as markers for breast cancer
17. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer
18. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma
19. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements
20. CA15.3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases
21. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse
22. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients
23. Breast cancer and clinical utility of CA15.3 and CEA
24. Use of serum tumor markers for the diagnosis and follow-up of breast cancer
25. Kinetic use of tumor markers in the follow-up of patients operated for primary breast cancer
26. Tumour markers in breast cancer: EGTM recommendations
27. A tumor marker utility grading system (TUUGS): A framework to evaluate clinical utility of tumor markers
28. Assessing the clinical impact of prognostic factors: When is "statistical significant" clinically useful?
29. Evaluation of patients following primary therapy
30. A novel method for monitoring high-risk breast cancer with tumor markers: CA15.3 compared to CEA and TPA
31. Analysis of repeated markers used to predict progression of cancer
32. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15.3
33. Variability of tumor markers in the follow-up of patients radically resected for breast cancer
34. Evaluation of critical differences of CEA and CA 15.3 levels in serial samples from patients operated for breast cancer
35. Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment